MARKET WIREYahoo! Finance Canada • 16h ago
Organon & Co. (OGN) Stock Price, News, Quote & HistoryYahoo! Finance Canada report covering Organon & Co. (OGN) market action, institutional positioning, and fundamental catalysts.
Why OGN Stock advanced +0.22% Today — RQD Quant Desk Flash
$13.84 +0.22% NYSE • Live Quote vs Prior Daily Close (Synced Snapshot)
EXT / AFTER-HRS: $13.88
Organon & Co. (OGN) earns a Roarable Rating of B- (Buy) with 70/100 RQD Confidence. High-quality cash engine (53% profit margin, 25% return on capital) with steady institutional support. The company’s underlying cash engine and institutional positioning keep the composite score in the Green Buy zone.
ROARABLE B- • BUY
Cap $3.63B
⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER
Click Any Pre-Computed AI Quant Specialist Briefing on OGN Below — or Connect Your Own ChatGPT / Claude
🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief)
Is OGN stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
▼
As of 2026-11-03, Organon & Co. (NYSE: OGN) is rated B- (Buy / BUY) by Roarable's 5-pillar RQD engine with a composite confidence score of 70/100 at a spot price of $13.84 (+0.22% 1D, market cap $3.63B). Pillar breakdown: Fundamental Cash Engine 18/20, Institutional 13F & Options Flow 16/20, Executive Insider Alignment 11/20, FRED Macro Regime Fit 9/20, and SEC Balance-Sheet Forensics 16/20. Across 1016 tracked Health Care issuers, OGN ranks #77 in composite RQD confidence.
✓ Pre-computed one-to-many AI Quant brief
🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief)
How does OGN compare to XENE and AMLX in the Health Care sector?
▼
Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), OGN carries a Roarable B- (70/100 RQD), trailing P/E of 19.4x, gross margin of 53.3%, and ROIC of 24.9%. By comparison, XENE (Xenon Pharmaceuticals Inc.) holds a D- grade (37/100 RQD, P/E N/A, ROIC -35.0%, cap $3.62B) and AMLX (Amylyx Pharmaceuticals Inc.) posts a D- grade (39/100 RQD, P/E N/A, ROIC -35.0%, cap $3.62B). Among the 5-stock peer group, ACAD leads on earnings multiple (9.1x) while OGN leads on capital efficiency (24.9% ROIC).
✓ Pre-computed one-to-many AI Quant brief
🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief)
What are the biggest fundamental strengths and SEC risk factors for OGN?
▼
Per OGN's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001821825), Organon & Co. generated $6.22B in revenue (-2.9% YoY), $187.0M in net income, and $538.0M in free cash flow against $12.87B in total assets and $8.63B in total debt. Key quantitative strengths: Strong cash generator (53% profit margin)—profits are backed by real money, not accounting tricks.. Primary risk factors monitored: Sensitive to high interest rates and tighter Federal Reserve market liquidity.. Institutional options positioning shows a 50% call / 50% put premium split.
✓ Pre-computed one-to-many AI Quant brief
🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).
INTERACTIVE SCENARIO DECK:
EXT / AFTER-HRS: $13.88 (+0.28%)🧬 Cannibal Buyback (-2.36% YoY Shares)⚙️ Cash Engine: 18/20 (A) • 8.7% FCF Margin
Verify 90D Bucket Audit →📊 Historical Track Record: Scores of 70/100 (B-) historically ranked in the Top 15% of excess returns over the next 90 days (+6.6% avg 90D alpha vs SPY • 68.1% hit rate).
Audit Bucket Track Record →RQD QUANT TACHOMETERBUY • B-
2-of-3 JEV AI Jury Bullish
Cash
SEC
Whale
Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer
5-PILLAR SNOWFLAKE RADARRw A- · Rk D
Each axis scored 0–20
12M PRICE TARGET CONE+5.4% Base Target
WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for OGN)Realized 20D OHLCV Swing Band: ±1.8%
Deterministic 5-Pillar Attribution (70/100 Composite)
🔍 WHY OGN SCORES 70/100 (B-) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag
▲ #1 Bullish Driver: Cash Engine Quality+18/20 pts (26% of score)
SEC XBRL FY 2025 (10-K): 8.7% FCF Margin ($538.0M FCF) & 53.3% Gross Margin
▲ #2 Bullish Driver: Whale & Options Positioning+16/20 pts (23% of score)
20D Institutional Volume Accumulation (±1.8% realized swing band)
▼ #1 Drag / Risk Factor: Macro Regime Fit9/20 pts (-11 pt drag)
Macro rate sensitivity & RSI-14 (64.5) create a -11 pt regime headwind
📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current
Q1 (-3Q)Grade C+$13.77-0.1% Next Q
62
Q2 (-2Q)Grade C+$13.76-0.1% Next Q
65
Q3 (-1Q)Grade B-$13.75+0.7% Next Q
67
CurrentGrade B-$13.84+6.6% Hist 90D α
70
Trajectory: C+ (62) → B- (70)Full Audit →
⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)GIDEON ASHMERE // FORENSIC SHORT & KILL-SWITCH DOSSIER
⚔️ Adversarial Opposing Case: Why the OGN Bull Thesis Could Fail
Even with a 70/100 (B-) score, OGN faces multiple-compression risk if 19.4x trailing P/E re-rate toward historical sector medians or if hyperscaler/enterprise customer concentration slows in upcoming 10-Q filings.
⚠️ Forensic Kill-Switch #1
Sensitive to high interest rates and tighter Federal Reserve market liquidity.
⚠️ Forensic Kill-Switch #2
Recent SEC filings added new risk-factor disclosures that warrant keeping an eye on margins.
⚠️ Forensic Kill-Switch #3
Technical & Forensic Kill-Switch: A daily close below the 50D SMA ($13.74) or 200D SMA ($11.57) invalidates the momentum regime and cuts Target Base ($14.59) toward Bear Floor ($11.35).
🎲 LIVE PREDICTION MARKET ODDS TIED TO $OGN• $2.4M Crowd Pool • Kalshi / Polymarket Composite
Contract: “OGN Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”
AUTOMATED RQD QUANT DESK MOVER BRIEFINGFull Market News Desk →
Why OGN Stock advanced +0.22% Today — RQD Quant Desk Flash
Organon & Co. (OGN) advanced +0.22% to $13.84, trading at 99% of its 52-week range ($5.69 – $13.84). High-quality cash engine (53% profit margin, 25% return on capital) with steady institutional support.
- ▸Technical Tape: Trading at 99% of its 52-week range ($5.69 – $13.84) with RSI-14 at 64.5 (BULLISH MOMENTUM).
- ▸Volatility Profile: Historical 20-day realized swing band of ±1.8% around $13.84 (no active unusual options sweep snapshot on file).
- ▸Fundamental Anchor: Roarable B- (Buy) backed by 53.3% gross margin and $538.0M annual free cash flow.
Live OGN Headlines & Catalysts
MARKET WIREYahoo Finance Singapore • 19h ago
Organon & Co. (OGN) stock price, news, quote and historyYahoo Finance Singapore report covering Organon & Co. (OGN) market action, institutional positioning, and fundamental catalysts.
MARKET WIREInvesting.com • 22h ago
Organon & Co stock hits 52-week high at 13.79 USDInvesting.com report covering Organon & Co. (OGN) market action, institutional positioning, and fundamental catalysts.
MARKET WIREYahoo Finance • 1d ago
Organon & Co. (OGN) Is a Trending Stock: Facts to Know Before Betting on ItYahoo Finance report covering Organon & Co. (OGN) market action, institutional positioning, and fundamental catalysts.
MARKET WIREStock Titan • 1d ago
Q3 revenue fell to $1.57B at Organon (OGN), but profit moved the other way.Stock Titan report covering Organon & Co. (OGN) market action, institutional positioning, and fundamental catalysts.
MARKET WIREYahoo Finance • 1d ago
Investors Heavily Search Organon & Co. (OGN): Here is What You Need to KnowYahoo Finance report covering Organon & Co. (OGN) market action, institutional positioning, and fundamental catalysts.
MARKET WIREad-hoc-news.de • 1d ago
Organon stock reaches new 52-week high at USD 13.83ad-hoc-news.de report covering Organon & Co. (OGN) market action, institutional positioning, and fundamental catalysts.
RISK WATCHhttps://www.dars.gov.et/ • 1d ago
Organon & Co. (OGN) Holds at $13.75 as Shares Consolidate Between Key Levels - Bear Flaghttps://www.dars.gov.et/ report covering Organon & Co. (OGN) market action, institutional positioning, and fundamental catalysts.
MARKET WIREYahoo • 2d ago
Organon (OGN) Q3 Results Highlight A Thin Margin CushionOrganon stock barely budged after Q3 2026 earnings, inching up just 0.2% to US$13.84, yet the fresh numbers tell a more charged story than the muted tape suggests. The latest quarter delivered basic earnings per share of
MARKET WIREYahoo • 3d ago
Organon (OGN) Q3 Earnings and Revenues Top EstimatesOrganon (OGN) delivered earnings and revenue surprises of +3.30% and +0.43%, respectively, for the quarter ended September 2026. Do the numbers hold clues to what lies ahead for the stock?
ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Quantitative Research Desk
Scheduled RQD Strong Buys & Whale Accumulation Briefing (OGN Tape Review)
- ✓Breakdown of the highest-scoring RQD Green-Light breakouts across our 5,200+ rated universe
- ✓Forensic Red-Light accounting & dilution traps to review on your watchlist
- ✓Includes downloadable .ics calendar invite & nightly RQD rating-change email alerts
RQD INSIDER CLUB WAITLIST$49/YR PLANNED
Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?
OGN // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: +4.37%⚡ TESTING RESISTANCE
2026-11-03O $13.81H $13.84L $13.81C $13.84VOL 1.85M
RES: $13.86SUP: $13.76SMA50: $13.74SMA200: $11.57
PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK
OGN Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure
Share Count & Dilution Monitor (#25)
Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).
Reverse-DCF Expectations Hurdle (#30)
12.8%/yr Implied 5Y Growth
vs. -2.9% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).
Ellis Vennor Setup Ledger (#33)
No active Ellis Vennor swing setup published on OGN today. View full Setup Ledger →
🦋 Documented & Second-Order Butterfly Connections
Open Graph →
No direct multi-tier Butterfly edges indexed yet for OGN. Explore sector supply chains on /butterfly.
AI Analyst Theses, Washington Policy & Company Video
🎬 No recent verified company-specific video clip queued for OGN today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →
DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK
📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (OGN)
Health Care Rank #77 of 1016
⚔️ XENE vs OGN Full Matrix →
1. Head-to-Head Health Care Peer Comparison (OGN vs. XENE, AMLX, IRON, ACAD)
Industry: Biotechnology: Pharmaceutical Preparations (489 Tracked Issuers)Across 1016 tracked Health Care securities in the Roarable RQD universe, Organon & Co. (OGN) ranks #77 by composite RQD confidence (70/100, grade B-) and #189 by equity capitalization ($3.63B). Within this direct 5-issuer industry benchmark cohort, ACAD leads on earnings valuation at 9.1x trailing P/E, while OGN leads on capital efficiency and profitability with 24.9% ROIC and 53.3% gross margin. OGN currently leads its immediate peer cohort in composite quantitative strength at 70/100 (B-).
| Ticker / Company | Roarable Grade | RQD Score | Trailing P/E | Gross Margin | ROIC | 1D Change | Market Cap | Head-to-Head |
|---|---|---|---|---|---|---|---|---|
| OGN
ACTIVE
Organon & Co. | B- | 70/100 | 19.4x | 53.3% | 24.9% | +0.22% | $3.63B | Benchmark Subject |
| XENE Xenon Pharmaceuticals Inc. | D- | 37/100 | — | — | -35.0% | -0.35% | $3.62B | /xene-vs-ogn → |
| AMLX Amylyx Pharmaceuticals Inc. | D- | 39/100 | — | — | -35.0% | +0.63% | $3.62B | /amlx-vs-ogn → |
| IRON Disc Medicine Inc. | D+ | 54/100 | — | — | -27.5% | -2.41% | $3.59B | /iron-vs-ogn → |
| ACAD ACADIA Pharmaceuticals Inc. | D | 49/100 | 9.1x | 91.7% | 7.9% | -0.82% | $3.55B | /acad-vs-ogn → |
2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)
SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001821825In its most recent audited fiscal period (FY2025, filed 2025-12-31), Organon & Co. (OGN) reported GAAP revenue of $6.22B (-2.9% vs. FY2024 revenue of $6.40B , and -0.8% cumulative change since FY2023) , GAAP net income of $187.0M, operating cash flow of $700.0M, and free cash flow of $538.0M (-29.6% YoY). On the balance sheet, OGN closed FY2025 with $12.87B in total assets against $8.63B in total debt (Altman Z-Score: N/A, Piotroski F-Score: 6/9).
| Fiscal Period | Filing Date | Revenue | Net Income | Operating Cash Flow | Free Cash Flow | Total Assets | Total Debt |
|---|---|---|---|---|---|---|---|
| FY2025 (FY) | 2025-12-31 | $6.22B | $187.0M | $700.0M | $538.0M | $12.87B | $8.63B |
| FY2024 (FY) | 2024-12-31 | $6.40B | $864.0M | $939.0M | $764.0M | $13.10B | $8.86B |
| FY2023 (FY) | 2023-12-31 | $6.26B | $1.02B | $799.0M | $799.0M | — | — |
3. OGN Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)
✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLEDIs OGN stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
As of 2026-11-03, Organon & Co. (NYSE: OGN) is rated B- (Buy / BUY) by Roarable's 5-pillar RQD engine with a composite confidence score of 70/100 at a spot price of $13.84 (+0.22% 1D, market cap $3.63B). Pillar breakdown: Fundamental Cash Engine 18/20, Institutional 13F & Options Flow 16/20, Executive Insider Alignment 11/20, FRED Macro Regime Fit 9/20, and SEC Balance-Sheet Forensics 16/20. Across 1016 tracked Health Care issuers, OGN ranks #77 in composite RQD confidence.
How does OGN compare to XENE and AMLX in the Health Care sector?
Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), OGN carries a Roarable B- (70/100 RQD), trailing P/E of 19.4x, gross margin of 53.3%, and ROIC of 24.9%. By comparison, XENE (Xenon Pharmaceuticals Inc.) holds a D- grade (37/100 RQD, P/E N/A, ROIC -35.0%, cap $3.62B) and AMLX (Amylyx Pharmaceuticals Inc.) posts a D- grade (39/100 RQD, P/E N/A, ROIC -35.0%, cap $3.62B). Among the 5-stock peer group, ACAD leads on earnings multiple (9.1x) while OGN leads on capital efficiency (24.9% ROIC).
What are the biggest fundamental strengths and SEC risk factors for OGN?
Per OGN's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001821825), Organon & Co. generated $6.22B in revenue (-2.9% YoY), $187.0M in net income, and $538.0M in free cash flow against $12.87B in total assets and $8.63B in total debt. Key quantitative strengths: Strong cash generator (53% profit margin)—profits are backed by real money, not accounting tricks.. Primary risk factors monitored: Sensitive to high interest rates and tighter Federal Reserve market liquidity.. Institutional options positioning shows a 50% call / 50% put premium split.
Where is OGN trading relative to its 50-day, 200-day, and 52-week technical levels?
OGN last traded at $13.84 (+0.22% on volume of 1,848,197 shares), positioning the stock +0.73% above its 50-day simple moving average ($13.74) and +19.62% above its 200-day simple moving average ($11.57). Across its 52-week range of $5.69 to $13.84, OGN sits at the 100.0% percentile with a 14-day RSI of 64.5 (BULLISH MOMENTUM) and an implied next-earnings move of ±1.8% ($13.59 to $14.09).
OGN Investor FAQ & Complete 8-Part Research Index
100% OPEN ACCESS • SEC EDGAR × CBOE × FREDWhy is OGN stock moving today?
Why OGN Stock advanced +0.22% Today — RQD Quant Desk Flash. High-quality cash engine (53% profit margin, 25% return on capital) with steady institutional support.
ROARABLE RATING BRIEF • RQD 70/100 (B-)
✓ STAGE-C NUMBER FIREWALL VERIFIED
OGN — Organon & Co.: What the Facts Mean to a Prospective Investor
Engine: anthropic/claude-haiku-5.5
As of: 2026-11-02T15:23:05Z
Roarable Rating Brief: What This Means to a Prospective Investor
Per the Roarable RQD rating, OGN scores 70 out of 100, a letter grade of B-, with the verdict label "Roarable Buy — Sound Institutional Accumulation." The fundamental cash engine pillar scores 18 of 20, supported by ROIC of 24.9% and an FCF yield of 14.83%, which is the strongest component of the rating and suggests the business generates substantial returns relative to capital employed. The whale 13F flow pillar scores 16 of 20 and the insider conviction pillar scores 16 of 20, both reflecting institutional accumulation and SEC Form 4 and Congressional PTR cluster flow as described in the rating. The forensic balance sheet pillar scores 11 of 20, reflecting an Altman Z of 2.5, a Piotroski F of 6 out of 9, and a Debt/Equity of 8.5. The macro regime fit pillar is the weakest at 9 of 20, reflecting a beta of 1.0 and sector sensitivity. For a prospective investor, the upside case rests on cash generation and capital returns, while the valuation and balance sheet tradeoffs are the principal considerations. The rating is a model output and does not constitute personalized financial advice.
Business
Organon & Co. (OGN) is a NYSE-listed issuer classified in the Health Care sector and the Biotechnology: Pharmaceutical Preparations industry, per the profile section. Source data does not describe its specific products, customers, or revenue model. Per the SEC financials, the company reported revenue of $6216.0M for FY 2025. Per the Butterfly Supply-Chain Graph, the supply chain is recorded as "NONE."
Financial Trend
| Period | Revenue | Operating Income | Net Income | EPS | FCF | Cash | Debt |
|---|---|---|---|---|---|---|---|
| FY 2025 | $6216.0M | $0.0M | $187.0M | N/A | $538.0M | $574.0M | $8628.0M |
| FY 2024 | $6403.0M | $0.0M | $864.0M | N/A | $764.0M | $675.0M | $8860.0M |
| FY 2023 | $6263.0M | $0.0M | $1023.0M | N/A | $799.0M | N/A | N/A |
Per the SEC financials, revenue declined from $6403.0M in FY 2024 to $6216.0M in FY 2025, and net income declined from $864.0M to $187.0M over the same period. Per the market data, gross margin is 53.3%, operating margin is 0%, and net margin is 3%. The RQD rating cites ROIC of 24.9%, an Altman Z of 2.5, and a Piotroski F of 6 out of 9. Debt was $8628.0M against cash of $574.0M at FY 2025, and the rating cites a Debt/Equity of 8.5.
Recent Catalysts & News Wire Analysis
Per the recent news section, five wire items reference OGN and are all tagged as market wire with a yellow signal. Headlines include a 52-week high report at 13.79 USD from Investing.com and a Stock Titan item stating that Q3 revenue fell to $1.57B while profit moved the other way. The remaining items are general quote and trending-stock pages without specific catalyst content. Per the Butterfly Supply-Chain Graph, there are no butterfly links and no proprietary signals.
Butterfly Effect: 2nd-Order Supply-Chain & Sector Ripples
Per the Butterfly Supply-Chain Graph, supply_chain is "NONE" and no butterfly links are recorded. Upstream and downstream dependencies, sector correlations, and second-order bottlenecks are not available in source data. The only sector context provided is the Health Care classification.
Open Questions
- What drives the decline in net income from $1023.0M in FY 2023 to $187.0M in FY 2025, and is it recurring or one-time?
- Why is operating income reported as $0.0M across all periods, and how should the 0% operating margin be interpreted?
- What is the company's debt maturity profile and interest burden relative to its $8628.0M debt load?
- What products and customers generate the revenue, and what is the supply-chain dependency structure?
- What are the analyst consensus, price targets, and 13F or insider holdings beyond the rating's qualitative description?
OGN Live News Feed, Press Releases & Catalyst Wire
Real-time company headlines, analyst actions, and sector developments for Organon & Co. (OGN) • Click "Debate This Headline" to argue it in the Roar Pit below
🟡 MARKET WIRE Yahoo! Finance Canada • 16h ago
Organon & Co. (OGN) Stock Price, News, Quote & History Yahoo! Finance Canada report covering Organon & Co. (OGN) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE Yahoo Finance Singapore • 19h ago
Organon & Co. (OGN) stock price, news, quote and history Yahoo Finance Singapore report covering Organon & Co. (OGN) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE Investing.com • 22h ago
Organon & Co stock hits 52-week high at 13.79 USD Investing.com report covering Organon & Co. (OGN) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE Yahoo Finance • 1d ago
Organon & Co. (OGN) Is a Trending Stock: Facts to Know Before Betting on It Yahoo Finance report covering Organon & Co. (OGN) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE Stock Titan • 1d ago
Q3 revenue fell to $1.57B at Organon (OGN), but profit moved the other way. Stock Titan report covering Organon & Co. (OGN) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE Yahoo Finance • 1d ago
Investors Heavily Search Organon & Co. (OGN): Here is What You Need to Know Yahoo Finance report covering Organon & Co. (OGN) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE ad-hoc-news.de • 1d ago
Organon stock reaches new 52-week high at USD 13.83 ad-hoc-news.de report covering Organon & Co. (OGN) market action, institutional positioning, and fundamental catalysts.
🔴 RISK WATCH https://www.dars.gov.et/ • 1d ago
Organon & Co. (OGN) Holds at $13.75 as Shares Consolidate Between Key Levels - Bear Flag https://www.dars.gov.et/ report covering Organon & Co. (OGN) market action, institutional positioning, and fundamental catalysts.
🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE
3 Active Posts & Replies
OGN Bull vs. Bear Conversation Board — What's Your Call at $13.84?
🐂 67% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON OGN 🐻 33% BEARISH CONVICTION
RO RoarDesk_Moderator Roarable Research Desk 🐂 BULLISH
🎯 Target: $16.30 (+18.0%)
📌 Pinned Debate 🔥 Official Bull vs. Bear Debate: Is OGN (B- • RQD 70/100) a Buy at $13.81?
Welcome to the OGN (Organon & Co.) Roar Pit. Current RQD Composite is 70/100 (Roarable Buy — Sound Institutional Accumulation) in Biotechnology: Pharmaceutical Preparations. Bulls point to capital efficiency (24.9% ROIC), while bears focus on macro rate sensitivity and margin execution. Pick your side (🐂 Bull or 🐻 Bear) and drop your price target below.
VA ValDiscipline Forensic Accounting Watch 🐻 BEARISH
🎯 Target: $11.05 (-20.0%)
Spot @ $13.81 Pump the brakes on OGN — check the valuation vs. margin headwinds
Everyone in here is repeating the bull case on OGN, but look at what you are paying: 19.4x trailing P/E with 53.3% gross margins. Unless Organon & Co. expands free cash flow yield next quarter, I would rather wait for a pullback closer to the 200-day moving average before touching this.
MI MidwestValue Verified K Arena Trader 🐂 BULLISH
🎯 Target: $16.30 (+18.0%)
Spot @ $13.81 OGN cash flow & RQD setup is being underpriced by the Street here
Looking at the 5-pillar RQD breakdown on OGN, the market is fixating on short-term headline noise in Biotechnology: Pharmaceutical Preparations and ignoring the balance sheet and cash flow trajectory. At $13.81 (52-wk range $5.69 - $13.84), any beat on forward guidance forces shorts and underweight funds to chase.